Post by Bachem

The rise of GLP‑1 therapies is reshaping the peptide industry. As demand shifts from kilogram-scale to multi‑kilogram, or even ton-scale production, peptide manufacturing is moving beyond traditional approaches toward industrial-scale operations. With this transformation come new challenges, including capacity constraints, sustainability considerations, and the need for infrastructure investment. This raises an important question for manufacturers: what does it take to keep up? Read our latest article, "GLP-1 Demand: What it means for peptide manufacturers", to explore these developments in detail. Link in the comments. #Bachem #Peptides #Manufacturing #GLP-1

Video Content